Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase

被引:21
|
作者
Awoonor-Williams, Ernest [1 ,2 ]
Rowley, Christopher N. [3 ]
机构
[1] Mem Univ Newfoundland, Dept Chem, St John, NF A1B 3X9, Canada
[2] Novartis Inst BioMed Res, 181 Massachusetts Ave, Cambridge, MA 02139 USA
[3] Carleton Univ, Dept Chem, Ottawa, ON K1S 5B6, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
FREE-ENERGY CALCULATIONS; PROTEIN-KINASES; DRUG DISCOVERY; SIDE-CHAINS; GLEEVEC; SELECTIVITY; MODIFIERS; POTENCY; DESIGN; ABL;
D O I
10.1021/acs.jcim.1c00897
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Targeted covalent inhibitors (TCIs) bind to their targets in both covalent and noncovalent modes, providing exceptionally high affinity and selectivity. These inhibitors have been effectively employed as inhibitors of protein kinases, with Taunton and coworkers (Nat. Chem. Biol. 2015, 11, 525-531) reporting a notable example of a TCI with a cyanoacrylamide warhead that forms a covalent thioether linkage to an active-site cysteine (Cys481) of Bruton's tyrosine kinase (BTK). The specific mechanism of the binding and the relative importance of the covalent and noncovalent interactions is difficult to determine experimentally, and established simulation methods for calculating the absolute binding affinity of an inhibitor cannot describe the covalent bond-forming steps. Here, an integrated approach using alchemical free-energy perturbation and QM/MM molecular dynamics methods was employed to model the complete Gibbs energy profile for the covalent inhibition of BTK by a cyanoacrylamide TCI. These calculations provide a rigorous and complete absolute Gibbs energy profile of the covalent modification binding process. Following a classic thiol-Michael addition mechanism, the target cysteine is deprotonated to form a nucleophilic thiolate, which then undergoes a facile conjugate addition to the electrophilic functional group to form a bond with the noncovalently bound ligand. This model predicts that the formation of the covalent linkage is highly exergonic relative to the noncovalent binding alone. Nevertheless, noncovalent interactions between the ligand and individual amino acid residues in the binding pocket of the enzyme are also essential for ligand binding, particularly van der Waals dispersion forces, which have a larger contribution to the binding energy than the covalent component in absolute terms. This model also shows that the mechanism of covalent modification of a protein occurs through a complex series of steps and that entropy, conformational flexibility, noncovalent interactions, and the formation of covalent linkage are all significant factors in the ultimate binding affinity of a covalent drug to its target.
引用
收藏
页码:5234 / 5242
页数:9
相关论文
共 50 条
  • [31] An inhibitor of Bruton's tyrosine kinase (BTK) from a fungal extract.
    Kawakami, T
    Kawakami, Y
    Hartman, SE
    Kinoshita, E
    Suzuki, H
    Kitaura, J
    Yao, L
    Inagaki, N
    Hata, D
    Maeda-Yamamoto, M
    Fukamachi, H
    Nagai, H
    FASEB JOURNAL, 1999, 13 (04): : A324 - A324
  • [32] Evobrutinib, a Bruton′s tyrosine kinase inhibitor, modulates microglia activity in vivo
    Geladaris, A.
    Torke, S.
    Haselmayer, P.
    Boschert, U.
    Brueck, W.
    Weber, M. S.
    GLIA, 2023, 71 : E946 - E946
  • [33] Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
    Anna Turetsky
    Eunha Kim
    Rainer H. Kohler
    Miles A. Miller
    Ralph Weissleder
    Scientific Reports, 4
  • [34] Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib
    Liu, Linyi
    Shi, Bingyu
    Wang, Xiangqian
    Xiang, Hua
    FUTURE MEDICINAL CHEMISTRY, 2018, 10 (03) : 343 - 356
  • [35] Inhibitor of Bruton's Tyrosine Kinase-α (IBTKα) in the Unfolded Protein Response
    Amin, Parth
    Mirek, Emily
    Staschke, Kirk
    Anthony, Tracy
    Wek, Ronald
    FASEB JOURNAL, 2021, 35
  • [36] Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy
    Taneja, Alankrita
    Jones, Jade
    Pittaluga, Stefania
    Maric, Irina
    Farooqui, Mohammed
    Ahn, Inhye E.
    Wiestner, Adrian
    Sun, Clare
    LEUKEMIA & LYMPHOMA, 2019, 60 (02) : 519 - 522
  • [37] Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
    Turetsky, Anna
    Kim, Eunha
    Kohler, Rainer H.
    Miller, Miles A.
    Weissleder, Ralph
    SCIENTIFIC REPORTS, 2014, 4
  • [38] Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis
    Brochard, J.
    Morio, F.
    Mahe, J.
    Le Pape, P.
    Guimard, T.
    Mahe, B.
    Leterrier, M.
    Morrier, M.
    Raffi, F.
    Boutoille, D.
    MEDECINE ET MALADIES INFECTIEUSES, 2020, 50 (08): : 742 - 745
  • [39] Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
    Caldwell, Richard D.
    Qiu, Hui
    Askew, Ben C.
    Bender, Andrew T.
    Brugger, Nadia
    Camps, Montserrat
    Dhanabal, Mohanraj
    Dutt, Vikram
    Eichhorn, Thomas
    Gardberg, Anna S.
    Goutopoulos, Andreas
    Grenningloh, Roland
    Head, Jared
    Healey, Brian
    Hodous, Brian L.
    Huck, Bayard R.
    Johnson, Theresa L.
    Jones, Christopher
    Jones, Reinaldo C.
    Mochalkin, Igor
    Morandi, Federica
    Ngan Nguyen
    Meyring, Michael
    Potnick, Justin R.
    Santos, Dusica Cvetinovic
    Schmidt, Ralf
    Sherer, Brian
    Shutes, Adam
    Urbahns, Klaus
    Follis, Ariele Viacava
    Wegener, Ansgar A.
    Zimmerli, Simone C.
    Liu-Bujalski, Lesley
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (17) : 7643 - 7655
  • [40] Separation of Bruton's tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography
    Yip, Shiuhang Henry
    Wu, Dauh-Rurng
    Li, Peng
    Sun, Dawn
    Watterson, Scott H.
    Zhao, Rulin
    Tino, Joseph
    Mathur, Arvind
    JOURNAL OF CHROMATOGRAPHY A, 2019, 1586 : 106 - 115